Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA4 | P43681 | 3/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9373067 | 0.80 | CHRNB2 (0.46) | CHRNA4CHRNB2CHRNB4CHRNA3ALDH1A1 | |
| SCHEMBL16131795 | 0.80 | CHRNB2 (0.46) | CHRNA4CHRNB2CHRNB4CHRNA3ALDH1A1 | |
| SCHEMBL14634145 | 0.80 | CHRNA4 (0.51) | CHRNA4TDP1ALDH1A1POLBHPGD | |
| Water SCHEMBL28920578 | 0.80 | TDP1 (0.58) | TDP1ALDH1A1POLBHPGDMEN1 | |
| Water SCHEMBL19857510 | 0.78 | TDP1 (0.56) | TDP1ALDH1A1POLBHPGDMEN1 | |
| SCHEMBL38726 | 0.77 | TDP1 (0.61) | TDP1ALDH1A1POLBHPGDMEN1 | |
| SCHEMBL11904537 | 0.77 | TDP1 (0.61) | TDP1ALDH1A1POLBHPGDMEN1 | |
| SCHEMBL9372891 | 0.77 | CHRNA4 (0.44) | CHRNA4CHRNB2CHRNB4CHRNA3ALDH1A1 | |
| Carbon Dioxide SCHEMBL28262228 | 0.75 | TDP1 (0.54) | TDP1ALDH1A1POLBHPGDMEN1 | |
| Cyanide SCHEMBL11195524 | 0.75 | TDP1 (0.54) | TDP1ALDH1A1POLBHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807077-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-23 | — | — | EP | claimed |
| US-7705042-B2 | Class of arylamide compounds useful as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-27 | — | — | US | claimed |
| US-7662837-B2 | 4-cyano-1H-imidazole-2-carboxylic acid {2-cyclohex-1-enyl-4-[1-(2-dimethylamino-acetyl)-piperidin-4-yl]-phenyl}-amide; protein tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-16 | — | — | US | claimed |
| EP-1807407-B1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-29 | — | — | EP | claimed |
| US-7429603-B2 | Such as 5-nitro-furan-2-carboxylic acid (2-piperidin-1-yl-phenyl)-amide; diabetes, angiogenesis, psoriasis, restenosis, schizophrenia, rheumatoid arthritis, cardiovascular disease, cancer | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | claimed |
| EP-1951234-A2 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-06 | — | — | EP | claimed |
| EP-1812425-A2 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-01 | — | — | EP | claimed |
| EP-1807406-A2 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-18 | — | — | EP | claimed |
| EP-1807407-A1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-18 | — | — | EP | claimed |
| EP-1807077-A2 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-18 | — | — | EP | claimed |
| US-20060094081-A1 | Crystal structure of the c-fms kinase domain: applications and use of heterologous substitutions of kinase insert domains for crystallization | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-04 | — | — | US | claimed |
| WO-2006047277-A2 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-04 | — | — | WO | claimed |
| WO-2006047505-A2 | CRYSTAL STRUCTURE OF THE C-FMS KINASE DOMAIN | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-04 | — | — | WO | claimed |
| WO-2006047479-A2 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-04 | — | — | WO | claimed |
| WO-2006047504-A1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-04 | — | — | WO | claimed |
| EP-1631560-A2 | C-FMS KINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-03-08 | — | — | EP | claimed |
| US-20050131022-A1 | C-fms kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-16 | — | — | US | claimed |
| US-20050113566-A1 | Inhibitors of C-FMS kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-26 | — | — | US | claimed |
| US-20050004112-A1 | C-fms kinase inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | claimed |
| WO-2004096795-A2 | C-FMS KINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2004-11-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131022-A1 | C-fms kinase inhibitors | FLT3, FES, FGR | CHRNA4 4343/4885CHRNB2 4463/4885CHRNB4 4315/4885 |
| US-20060094081-A1 | Crystal structure of the c-fms kinase domain: applications and use of heterologous substitutions of kinase insert domains for crystallization | FLT3, FER, FES | CHRNA4 3542/4885CHRNB2 4053/4885CHRNB4 3509/4885 |
| US-20050004112-A1 | C-fms kinase inhibitors | FLT3, FGR, FER | CHRNA4 4296/4885CHRNB2 4308/4885CHRNB4 4219/4885 |
| US-20050113566-A1 | Inhibitors of C-FMS kinase | ALK, TYRO3, PDGFRB | CHRNA4 1369/4885CHRNB2 1457/4885CHRNB4 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.